MedTrace Logo

Growth Hormone Deficiency in Chronic Heart Failure: A Preliminary Trial

NCT00591760 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2012-11-19

Study results available
· View outcomes & findings →

Summary

The aim of this study is to investigate the potential benefits of the correction of growth hormone (GH) deficiency with GH replacement therapy in patients with chronic heart failure due to left ventricular systolic dysfunction.

Conditions

Interventions

DRUG

Somatotropin

Subcutaneous Somatotropin (recombinant human Growth Hormone) 0.012 mg/kg every second day for 6 months

Sponsors & Collaborators

  • Federico II University

    lead OTHER

Principal Investigators

  • Antonio Cittadini, MD · Federico II University - Naples

  • Luigi Saccà, MD · Federico II University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-12-31
Primary Completion
2007-11-30
Completion
2007-11-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00591760 on ClinicalTrials.gov